$ARTV Up 20% Premarket! 🚀 🔹 Artiva reported strong Q1 2026 updates, with AlloNK clinical data showing a 71% ACR50 response in refractory rheumatoid arthritis

$ARTV Up 20% Premarket! 🚀 🔹 Artiva reported strong Q1 2026 updates, with AlloNK clinical data showing a 71% ACR50 response in refractory rheumatoid arthritis patients with at least 6 months of follow-up 📈 🔹 No relapses or need for new immunomodulatory agents in those RA patients — a huge signal …